Estradiol suppresses tissue androgens and prostate cancer growth in castration resistant prostate cancer
© Montgomery et al; licensee BioMed Central Ltd. 2010
Received: 24 January 2010
Accepted: 28 May 2010
Published: 28 May 2010
Estrogens suppress tumor growth in prostate cancer which progresses despite anorchid serum androgen levels, termed castration resistant prostate cancers (CRPC), although the mechanisms are unclear. We hypothesize that estrogen inhibits CRPC in anorchid animals by suppressing tumoral androgens, an effect independent of the estrogen receptor.
The human CRPC xenograft LuCaP 35V was implanted into orchiectomized male SCID mice and established tumors were treated with placebo, 17β-estradiol or 17β-estradiol and estrogen receptor antagonist ICI 182,780. Effects of 17β-estradiol on tumor growth were evaluated and tissue testosterone (T) and dihydrotestosterone (DHT) evaluated by mass spectrometry.
Treatment of LuCaP 35V with 17β-estradiol slowed tumor growth compared to controls (tumor volume at day 21: 785 ± 81 mm3 vs. 1195 ± 84 mm3, p = 0.002). Survival was also significantly improved in animals treated with 17β-estradiol (p = 0.03). The addition of the estrogen receptor antagonist ICI 182,780 did not significantly change survival or growth. 17β-estradiol in the presence and absence of ICI 182,780 suppressed tumor testosterone (T) and dihydrotestosterone (DHT) as assayed by mass spectrometry. Tissue androgens in placebo treated LuCaP 35V xenografts were; T = 0.71 ± 0.28 pg/mg and DHT = 1.73 ± 0.36 pg/mg. In 17β-estradiol treated LuCaP35V xenografts the tissue androgens were, T = 0.20 ± 0.10 pg/mg and DHT = 0.15 ± 0.15 pg/mg, (p < 0.001 vs. controls). Levels of T and DHT in control liver tissue were < 0.2 pg/mg.
CRPC in anorchid animals maintains tumoral androgen levels despite castration. 17β-estradiol significantly suppressed tumor T and DHT and inhibits growth of CRPC in an estrogen receptor independent manner. The ability to manipulate tumoral androgens will be critical in the development and testing of agents targeting CRPC through tissue steroidogenesis.
The Nobel prize winning work of Huggins and Hodges described the use of estrogens and orchiectomy in the treatment of prostate cancer [1, 2]. With the development of LHRH agonists, and the recognition that oral estrogens carried a significant risk of vascular complications, LHRH agonists supplanted estrogens as a primary treatment for advanced disease . The use of diethylstilbestrol, and more recently transdermal estradiol, [4, 5] remains relevant because estrogens can induce PSA response rates as high as 45% in selected patients with early "androgen-independent" or castration resistant prostate cancer (CRPC) . Estrogens ameliorate toxicities associated with androgen deprivation by maintaining bone mineral density, suppressing hot flushes and improving both cognitive function and lipids in men with anorchid testosterone levels [7–9].
The relatively high response rate of castration resistant prostate cancer to secondary manipulations with estrogens and ketoconazole has been ascribed to suppression of adrenal androgen production [10, 11]. Other investigators have suggested that estrogens directly inhibit growth of prostate cancer when administered in vitro in the absence of circulating hormones . We have previously shown that 17β-estradiol suppressed CRPC growth and delayed mortality in multiple castration resistant xenograft models in vivo . In these castrate animals, estrogen suppressed tumor growth despite the lack of circulating testosterone, dehydroepiandrosterone (DHEA) and androstenedione synthesis, a feature resulting from a lack of CYP17 in murine adrenal glands . The estradiol inhibition of these human prostate cancer xenografts in castrated mice must therefore be independent of both testicular and adrenal androgens. Potential mechanisms of tumor suppression include receptor dependent inhibition through estrogen receptor β, [15, 16]or receptor independent mechanisms such as induction of immune surveillance, or metabolism of 17β-estradiol to cytotoxic estrogens such as 2-methoxyestradiol . We have demonstrated that metastases from men with progressive CRPC contain testosterone levels significantly higher than those in prostate cancer tissue from eugonadal men. Moreover, elevated tumoral androgens were associated with increased tumor transcripts encoding enzymes involved in the synthesis of androgens . These studies suggested that prostate cancer can maintain intratumoral androgens to aid in tumor progression in CRPC. In the current study we hypothesize that 17β-estradiol might inhibit CRPC growth in anorchid hosts and suppress tumoral androgens by competitively inhibiting steroidogenesis from cholesterol, and reduce available tumoral androgens that drive growth [19–22]
In the current study we analyzed the effect of estradiol on tissue androgen levels in the castration resistant LuCaP 35V human prostate xenograft, demonstrating suppression of tumoral androgens. Tumor suppression in this model by estradiol was independent of the estrogen receptor, suggesting that competitive inhibition of androgen metabolism within tumor tissue is another potential mechanism by which estradiol and other estrogens inhibit prostate cancer growth.
All procedures were performed in compliance with the University of Washington Institutional Animal Care and Use Committee and NIH guidelines. Four- to 6-week-old male SCID mice (Fox Chase SCID mice, Charles River, Wilmington, MA) were used. The animals were orchiectomized at 8 weeks of age, and all animals were implanted with tumors at least 2 weeks after surgery. Tumor bits (20-30 mm3) of human castration resistant prostate tumor xenograft LuCaP 35V were implanted subcutaneously. LuCaP 35 originated from a lymph node prostate cancer metastasis from a patient with androgen resistant prostate cancer. Both the castration sensitive (CS) LuCaP 35 and isogenic, castration resistant LuCaP 35V express PSA and a wild-type androgen receptor . Tumor growth was monitored by tumor measurements twice a week using calipers, and tumor volume was calculated as 0.5236 × LxHxW. When tumors reached 150 to 400 mm3, the animals were randomized into three groups. Group 1 (n = 10), the control group, were implanted with subcutaneous placebo pellets (Innovative Research of America, Sarasota, FL). Group 2 (n = 10): animals were supplemented with 17β-estradiol by subcutaneous implantation of slow-release Trocar pellets (90-day release, 0.36 mg; Innovative Research of America). Group 3 (n = 10): animals were implanted with 17β-estradiol pellets and the estrogen receptor antagonist ICI 182,780 was injected once a week (5 mg, subcutaneous injection) . Control tissue for androgens was assayed from non-xenograft tissue from the same animals as well as from isogenic castration sensitive LuCaP 35 growing in eugonadal male mice. Effects of the treatments were monitored by biweekly measurements of tumor volume. Animals were sacrificed when tumors exceeded 1000 mm3 or when the animals became compromised. Tumors were snap frozen in liquid nitrogen and stored at -80°C. Efficacy of the different treatment methods was assessed as average tumor volumes per group after 3 weeks of treatment. Growth delay was measured as the time from the start of treatment to the time for tumors to reach a volume of 1000 mm3 . All procedures were performed in compliance with the University of Washington Institutional Animal Care and Use Committee
The significance of differences in survival rate was tested using the log-rank statistic. Statistical significance between androgens in tissues of control and treated animals, differences in tumor volume at fixed intervals, and time to tumor volume of 1000 mm3 were assayed using Student's t test; 95% confidence interval, and P ≤ 0.05 was considered significant.
Androgen levels were determined by mass spectrometry (MS) using methods we have recently described . In brief, frozen tissue samples were individually thawed, weighed, and homogenized in PBS. The homogenates were extracted with 8 ml of diethyl ether and the organic phase decanted after freezing the aqueous phase in a dry ice/ethanol bath. The organic phase was dried and concentrated with 2 × 0.5 ml ether washes under a stream of purified air. Each individual concentrated extract was dissolved in 1.0 ml redistilled ethanol and stored at -20°C until MS analysis. Samples were spiked with internal standards: 50 pg of deuterated (D3)-DHT and D3-testosterone, vortexed briefly, and evaporated to dryness. The residue was then reconstituted in 0.5 mL of water prior to extraction with methylene chloride. The organic phase was removed under nitrogen and the sample was dissolved in 0.1 M hydroxylamine hydrochloride in 50% MeOH/water, vortexed, and heated at 60° for 1 hour. Standards for DHT and testosterone were prepared in parallel. The resulting oximes were analyzed by LC-MS-MS using a Waters Aquity HPLC and Premier XE mass spectrometer (Milford, MA). Ions monitored were 350 > 309 and 347 > 306 for DHT-IS and DHT respectively, and 307 > 124 and 304 > 124 for testosterone-IS and testosterone respectively. This procedure resulted in a lower limit of quantitation of 100 and 500 attoMoles on column for testosterone and DHT respectively. Intra-assay coefficients of variation generated using human serum for high, mid and low-range samples were 3.5, 3.1 and 3.8% for testosterone and 6.3, 4.3 and 15.8% for DHT respectively. Data for tissue androgens was derived from 2-5 tumor samples per data point. Estradiol levels were performed on mouse serum collected at the time of sacrifice and assayed by ELISA (IBL, Hamburg).
Effect of estradiol on tumor growth in orchiectomized mice
Tumor growth in response to 17β-estradiol and ICI 182,780
Tumor volume on Day 21 (mm3) (SE)
Days to 1000 mm3 (SE)
784.7 (81.1) *
25.7 (3.4) †,
675.2 (77.2) **
33.4 (4.4) ††
* p = 0.002 vs. control
†, p = 0.05 vs. control
** p = 0.001 vs. control.
†† p = 0.003 vs. control
Estradiol effects on tumoral testosterone and DHT levels
Estrogens have long played a role in the treatment of advanced prostate cancer, however the mechanism of efficacy in men who have already developed resistance to androgen-deprivation therapies has been uncertain. Estrogens induce feedback inhibition of LH secretion in patients with an intact hypothalamic-pituitary axis, resulting in decreased testosterone production. An early VA Cooperative Urology Group study compared the estrogen diethylstilbestrol (DES) to orchiectomy, and demonstrated that DES provided better cancer specific survival than orchiectomy, but cardiovascular mortality offset the improved disease control . This study raised the possibility that estrogens might inhibit cancer growth independently of simple suppression of testicular androgen production. In support of that idea, our group has previously shown that estradiol inhibits multiple castration resistant human prostate cancer xenografts in castrated animals, however the mechanism remained ambiguous. This study was carried out to determine if estrogen inhibition of prostate cancer xenograft growth was estrogen receptor dependent, and whether estrogen might be mediating its effect by suppressing tissue androgens which could support tumor survival and proliferation. The data presented here strongly suggest that estradiol inhibition of tumor growth in this setting is estrogen receptor independent, as ICI 182,780 blocks both ERα and β signaling, yet did not abrogate estradiol mediated tumor suppression. In addition, estradiol clearly suppressed tumor androgen levels, an effect for which there is no plausible mechanism in castrated animals lacking functional adrenal CYP17. The xenografts used in these studies express wild type AR, not mutant AR and are therefore not expected to bind estradiol. It was first reported by Geller, and subsequently by others that prostate tissue in androgen deprived individuals maintains levels of DHT and testosterone which are between 20 and 50% those found in tissue from eugonadal men [28–32]. Maintenance of these tissue levels despite anorchid serum levels might occur either through sequestration of androgens, or by metabolism or synthesis of androgens from earlier precursors. The idea of tissue "intracrine" synthesis of androgen was proposed initially by Labrie et al . This mechanism would incorporate the ability of estrogen to suppress tumor growth independent of gonadal or adrenal androgens. This report is the first to clearly demonstrate that prostate cancer xenografts maintain tissue androgens independent of endocrine function, in castrate hosts. It is also the first report that demonstrates that estradiol inhibition of tumor growth in this setting is not ER dependent and that estradiol effectively suppresses tumoral androgen levels, a result which might explain an ER independent mechanism of blocking castration resistant tumor growth. This data supports the concept that tissue androgens are not necessarily dependent on endocrine organ function. The importance of residual androgens is uncertain unless these tissue levels can be further suppressed to slow tumor growth, an effect which has been demonstrated in this study. Although not defined in these experiments, the most parsimonious explanation of the ability of estrogen to effect this change would be through its ability as a steroidal hormone to competitively inhibit the relatively promiscuous enzymes of steroidogenesis which might mediate tissue metabolism [19–22]. Multiple steroidal hormones are capable of interacting with steroid transporters and competitively inhibiting metabolism of other substrates, in any tissue which contains these enzymes.
Extrapolation of the results of xenograft studies to the biology of metastatic prostate cancer in man remains speculative. In patients with advanced prostate cancer, suppression of androgen production by orchiectomy or LHRH agonist administration has a transient, although significant impact on prostate cancer growth. Remarkably, despite the immediate clinical benefits of androgen deprivation, the tissue effects of suppressing serum androgen levels are much more modest. Our group has reported that benign prostate tissue as well as prostate cancers maintain physiologic levels of both testosterone and DHT despite effective suppression of serum androgens . The ability of prostate tissue to maintain local hormone levels is reflected in the minimal change in the expression of androgen regulated gene expression in men with anorchid serum androgens . These findings may explain the observation by Agus and colleagues that androgen deprivation in prostate cancer xenograft models demonstrated only transient cell cycle arrest, with little evidence of apoptosis, followed by relatively rapid progression . The persistence of tissue androgens despite anorchid serum levels would be anticipated to continue to support prostate cancer cell survival, and growth over time.
Estrogens, including, ethinyl estradiol, DES, and transdermal estradiol remain an option for patients with both androgen dependent and castration resistant prostate cancer [4–6, 35, 36]. The current study provides evidence that a component of estrogen activity occurs though reductions of tissue androgen levels even when serum androgens are completely suppressed by castration. The effect is independent of estrogen receptor, and suggests that further investigation of how tumoral androgens play a role in progressive CRPC are warranted. Studies to elucidate the mechanism(s) by which tissue androgens are maintained will be critical for understanding the importance of this phenomenon. This becomes more important as agents become available which can more effectively modulate interactions between intracrine ligands and the AR, including high affinity AR antagonists and agents which interfere with enzymes of steroidogenesis [37, 38]
The current study demonstrates that estradiol slows tumor progression of CRPC xenografts grown in orchiectomized mice. The inhibition of tumor progression is associated with the ability of estradiol to inhibit intratumoral androgen levels, which at baseline are unexpectedly higher than would be expected in the context of no serum testosterone, and a lack of serum DHEA. The use of estradiol receptor antagonist did not block estradiol inhibition of tumor growth, nor did it change the suppression of tumor androgens, suggesting that both effects are independent of estrogen receptor. This study suggests that the known ability of secondary hormonal manipulations to suppress CRPC growth is related to inhibition of tumoral androgens, and in this specific study is independent of adrenal DHEA production. This has implications for the design of future therapies targeting different arms of steroidogenesis in prostate cancer as more effective treatment.
We thank the patients and their families who made this work possible through their altruistic donation of tissues, and members of University of Washington Urology Department and Tissue Acquisition Necropsy team for assisting with sample collections. Grant support: Pacific Northwest Prostate Cancer SPORE pilot project (CA97196) (to RBM)
- Huggins C: Effect of Orchiectomy and Irradiation on Cancer of the Prostate. Ann Surg. 1942, 115 (6): 1192-1200. 10.1097/00000658-194206000-00030.View ArticlePubMedPubMed CentralGoogle Scholar
- Huggins C, Hodges CV: Studies on prostatic cancer. I. The effect of castration, estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941, 1: 293-297.Google Scholar
- Harris WP, Mostaghel EA, Nelson PS, Montgomery B: Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009, 6 (2): 76-85. 10.1038/ncpuro1296.View ArticlePubMedPubMed CentralGoogle Scholar
- Bland LB, Garzotto M, DeLoughery TG, Ryan CW, Schuff KG, Wersinger EM, Lemmon D, Beer TM: Phase II study of transdermal estradiol in androgen-independent prostate carcinoma. Cancer. 2005, 103 (4): 717-723. 10.1002/cncr.20857.View ArticlePubMedGoogle Scholar
- Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer [see comments]. Urology. 1998, 52 (2): 257-260. 10.1016/S0090-4295(98)00173-3.View ArticlePubMedGoogle Scholar
- Smith DC, Redman BG, Flaherty LE, Li L, Strawderman M, Pienta KJ: A phase II trial of oral diethylstilbesterol as a second-line hormonal agent in advanced prostate cancer. Urology. 1998, 52 (2): 257-260. 10.1016/S0090-4295(98)00173-3.View ArticlePubMedGoogle Scholar
- Purnell JQ, Bland LB, Garzotto M, Lemmon D, Wersinger EM, Ryan CW, Brunzell JD, Beer TM: Effects of transdermal estrogen on levels of lipids, lipase activity, and inflammatory markers in men with prostate cancer. J Lipid Res. 2006, 47 (2): 349-355. 10.1194/jlr.M500276-JLR200.View ArticlePubMedGoogle Scholar
- Beer TM, Bland LB, Bussiere JR, Neiss MB, Wersinger EM, Garzotto M, Ryan CW, Janowsky JS: Testosterone loss and estradiol administration modify memory in men. J Urol. 2006, 175 (1): 130-135. 10.1016/S0022-5347(05)00049-2.View ArticlePubMedGoogle Scholar
- Ockrim JL, Lalani EN, Banks LM, Svensson WE, Blomley MJ, Patel S, Laniado ME, Carter SS, Abel PD: Transdermal estradiol improves bone density when used as single agent therapy for prostate cancer. J Urol. 2004, 172 (6 Pt 1): 2203-2207. 10.1097/01.ju.0000145511.56476.00.View ArticlePubMedGoogle Scholar
- Harris KA, Weinberg V, Bok RA, Kakefuda M, Small EJ: Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol. 2002, 168 (2): 542-545. 10.1016/S0022-5347(05)64675-7.View ArticlePubMedGoogle Scholar
- Stege R, Eriksson A, Henriksson P, Carlstrom K: Orchidectomy or oestrogen treatment in prostatic cancer: effects on serum levels of adrenal androgens and related steroids. Int J Androl. 1987, 10 (4): 581-587. 10.1111/j.1365-2605.1987.tb00357.x.View ArticlePubMedGoogle Scholar
- Robertson CN, Roberson KM, Padilla GM, O'Brien ET, Cook JM, Kim CS, Fine RL: Induction of apoptosis by diethylstilbestrol in hormone-insensitive prostate cancer cells. J Natl Cancer Inst. 1996, 88 (13): 908-917. 10.1093/jnci/88.13.908.View ArticlePubMedGoogle Scholar
- Corey E, Quinn JE, Emond MJ, Buhler KR, Brown LG, Vessella RL: Inhibition of androgen-independent growth of prostate cancer xenografts by 17beta-estradiol. Clin Cancer Res. 2002, 8 (4): 1003-1007.PubMedGoogle Scholar
- van Weerden WM, Bierings HG, van Steenbrugge GJ, de Jong FH, Schroder FH: Adrenal glands of mouse and rat do not synthesize androgens. Life Sci. 1992, 50 (12): 857-861. 10.1016/0024-3205(92)90204-3.View ArticlePubMedGoogle Scholar
- Ho SM, Leung YK, Chung I: Estrogens and antiestrogens as etiological factors and therapeutics for prostate cancer. Ann N Y Acad Sci. 2006, 1089: 177-193. 10.1196/annals.1386.005.View ArticlePubMedGoogle Scholar
- Pravettoni A, Mornati O, Martini PG, Marino M, Colciago A, Celotti F, Motta M, Negri-Cesi P: Estrogen receptor beta (ERbeta) and inhibition of prostate cancer cell proliferation: studies on the possible mechanism of action in DU145 cells. Mol Cell Endocrinol. 2007, 263 (1-2): 46-54. 10.1016/j.mce.2006.08.008.View ArticlePubMedGoogle Scholar
- Qadan LR, Perez-Stable CM, Anderson C, D'Ippolito G, Herron A, Howard GA, Roos BA: 2-Methoxyestradiol induces G2/M arrest and apoptosis in prostate cancer. Biochem Biophys Res Commun. 2001, 285 (5): 1259-1266. 10.1006/bbrc.2001.5320.View ArticlePubMedGoogle Scholar
- Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS: Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008, 68 (11): 4447-4454. 10.1158/0008-5472.CAN-08-0249.View ArticlePubMedPubMed CentralGoogle Scholar
- Daehlin L, Hammar M, Damber JE, Berg AA, Petersson F: Effects of oestradiol-17 beta and ethinyl oestradiol on human testicular steroidogenesis in vitro. Scand J Urol Nephrol. 1986, 20 (3): 177-181. 10.3109/00365598609024490.View ArticlePubMedGoogle Scholar
- Guo IC, Wu LS, Lin JH, Chung BC: Differential inhibition of progesterone synthesis in bovine luteal cells by estrogens and androgens. Life Sci. 2001, 68 (16): 1851-1865. 10.1016/S0024-3205(01)00983-3.View ArticlePubMedGoogle Scholar
- Houk CP, Pearson EJ, Martinelle N, Donahoe PK, Teixeira J: Feedback inhibition of steroidogenic acute regulatory protein expression in vitro and in vivo by androgens. Endocrinology. 2004, 145 (3): 1269-1275. 10.1210/en.2003-1046.View ArticlePubMedGoogle Scholar
- Johnson DC: Cellular localization and factors controlling rat placental cytochrome P45017 alpha (CYP17): 17 alpha-hydroxylase/C17,20-lyase activity. Biol Reprod. 1992, 46 (1): 30-38. 10.1095/biolreprod46.1.30.View ArticlePubMedGoogle Scholar
- Corey E, Quinn JE, Buhler KR, Nelson PS, Macoska JA, True LD, Vessella RL: LuCaP 35: A new model of prostate cancer progression to androgen independence. Prostate. 2003, 55 (4): 239-246. 10.1002/pros.10198.View ArticlePubMedGoogle Scholar
- Chisamore MJ, Ahmed Y, Bentrem DJ, Jordan VC, Tonetti DA: Novel antitumor effect of estradiol in athymic mice injected with a T47 D breast cancer cell line overexpressing protein kinase Calpha. Clin Cancer Res. 2001, 7 (10): 3156-3165.PubMedGoogle Scholar
- Tang Y, Khan MA, Goloubeva O, Lee DI, Jelovac D, Brodie AM, Hussain A: Docetaxel followed by castration improves outcomes in LNCaP prostate cancer-bearing severe combined immunodeficient mice. Clin Cancer Res. 2006, 12 (1): 169-174. 10.1158/1078-0432.CCR-05-1388.View ArticlePubMedGoogle Scholar
- Page ST, Kalhorn TF, Bremner WJ, Anawalt BD, Matsumoto AM, Amory JK: Intratesticular androgens and spermatogenesis during severe gonadotropin suppression induced by male hormonal contraceptive treatment. J Androl. 2007, 28 (5): 734-741. 10.2164/jandrol.107.002790.View ArticlePubMedGoogle Scholar
- Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the Veterans Administration Cooperative Urological Research Group studies. NCI Monogr. 1988, 165-170. 7Google Scholar
- Geller J, Albert J, Nachtsheim D, Loza D, Lippman S: Steroid levels in cancer of the prostate--markers of tumor differentiation and adequacy of anti-androgen therapy. Prog Clin Biol Res. 1979, 33: 103-111.PubMedGoogle Scholar
- Geller J, de la Vega DJ, Albert JD, Nachtsheim DA: Tissue dihydrotestosterone levels and clinical response to hormonal therapy in patients with advanced prostate cancer. J Clin Endocrinol Metab. 1984, 58 (1): 36-40. 10.1210/jcem-58-1-36.View ArticlePubMedGoogle Scholar
- Mohler JL, Gregory CW, Ford OH, Kim D, Weaver CM, Petrusz P, Wilson EM, French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res. 2004, 10 (2): 440-448. 10.1158/1078-0432.CCR-1146-03.View ArticlePubMedGoogle Scholar
- Mostaghel EA, Page ST, Lin DW, Fazli L, Coleman IM, True LD, Knudsen B, Hess DL, Nelson CC, Matsumoto AM, et al: Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res. 2007, 67 (10): 5033-5041. 10.1158/0008-5472.CAN-06-3332.View ArticlePubMedGoogle Scholar
- Nishiyama T, Hashimoto Y, Takahashi K: The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res. 2004, 10 (21): 7121-7126. 10.1158/1078-0432.CCR-04-0913.View ArticlePubMedGoogle Scholar
- Labrie F, Belanger A, Dupont A, Luu-The V, Simard J, Labrie C: Science behind total androgen blockade: from gene to combination therapy. Clin Invest Med. 1993, 16 (6): 475-492.PubMedGoogle Scholar
- Agus DB, Cordon-Cardo C, Fox W, Drobnjak M, Koff A, Golde DW, Scher HI: Prostate cancer cell cycle regulators: response to androgen withdrawal and development of androgen independence. J Natl Cancer Inst. 1999, 91 (21): 1869-1876. 10.1093/jnci/91.21.1869.View ArticlePubMedGoogle Scholar
- Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM: Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer. Cancer. 2007, 110 (5): 996-1002. 10.1002/cncr.22917.View ArticlePubMedGoogle Scholar
- Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK: Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol. 2007, 177 (6): 2146-2150. 10.1016/j.juro.2007.01.119.View ArticlePubMedGoogle Scholar
- Haidar S, Ehmer PB, Barassin S, Batzl-Hartmann C, Hartmann RW: Effects of novel 17alpha-hydroxylase/C17, 20-lyase (P450 17, CYP 17) inhibitors on androgen biosynthesis in vitro and in vivo. J Steroid Biochem Mol Biol. 2003, 84 (5): 555-562.View ArticlePubMedGoogle Scholar
- Handratta VD, Vasaitis TS, Njar VC, Gediya LK, Kataria R, Chopra P, Newman D, Farquhar R, Guo Z, Qiu Y, et al: Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem. 2005, 48 (8): 2972-2984. 10.1021/jm040202w.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/10/244/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.